What is the recommended dosing and titration schedule for selexipag (oral prostacyclin receptor agonist) in adults with pulmonary arterial hypertension, including target dose, dose adjustments, contraindications, and monitoring?

Selexipag Dosing and Administration for Pulmonary Arterial Hypertension

Start selexipag at 200 mcg twice daily with food and titrate upward by 200 mcg twice daily at weekly intervals to the highest tolerated dose, with a maximum of 1,600 mcg twice daily. 1

Initial Dosing

• Standard starting dose: 200 mcg twice daily 1
• Take with food to improve tolerability 1
• Do not split, crush, or chew tablets 1

Titration Schedule

The titration follows an individualized approach based on patient tolerance:

• Increase by 200 mcg twice daily increments 1
• Titration interval: Usually weekly, though real-world practice may use slower titration (e.g., every other week) for better tolerability 2
• Target: Highest tolerated dose up to maximum of 1,600 mcg twice daily 1
• If dose not tolerated: Reduce to the previous tolerated dose 1

The landmark GRIPHON trial demonstrated that selexipag reduced the composite endpoint of death or PAH-related complications by 40% (HR 0.60, P<0.001), with consistent effects across low (200-400 mcg bid), medium (600-1000 mcg bid), and high (1200-1600 mcg bid) dose ranges 3, 4. Real-world data confirms that approximately 44% of patients achieve high doses, 30% medium doses, and 26% low doses, with similar outcomes across dose ranges when individualized appropriately 2.

Dose Adjustments for Special Populations

Hepatic Impairment

• Mild (Child-Pugh A): No adjustment needed 1
• Moderate (Child-Pugh B): Start at 200 mcg once daily (not twice daily), increase by 200 mcg once daily at weekly intervals 1
• Severe (Child-Pugh C): Avoid use 1

Drug Interactions

• With moderate CYP2C8 inhibitors (clopidogrel, deferasirox, teriflunomide): Reduce to once daily dosing 1
• With strong CYP2C8 inhibitors (gemfibrozil): Contraindicated 1
• With CYP2C8 inducers (rifampin): May increase dose up to twice the usual dose 1

Managing Missed Doses and Interruptions

• Single missed dose: Take as soon as possible unless next dose is within 6 hours 1
• Treatment interruption ≥3 days: Restart at a lower dose and retitrate 1

This is critical—patients cannot simply resume their previous dose after a 3-day gap due to loss of tolerance to prostacyclin effects.

Contraindications

• Absolute contraindications:
  • Hypersensitivity to selexipag or excipients 1
  • Concomitant use with strong CYP2C8 inhibitors (gemfibrozil) 1

Monitoring and Safety Considerations

Key Warning: Pulmonary Veno-Occlusive Disease

If signs of pulmonary edema develop, consider pulmonary veno-occlusive disease and discontinue selexipag if confirmed 1. This is the most serious safety concern.

Common Adverse Effects

The most frequent side effects (>5% more than placebo) include 1:

• Headache
• Diarrhea
• Jaw pain
• Nausea
• Myalgia
• Vomiting
• Pain in extremity
• Flushing

These are prostacyclin class effects and often improve with continued therapy. In clinical trials, 14.3% of selexipag patients discontinued due to adverse events versus 7.1% on placebo 4. Real-world data shows 19% discontinue due to tolerability 5.

Clinical Context and Efficacy

Selexipag is indicated for WHO Functional Class II-III PAH to delay disease progression and reduce hospitalization risk 1. The 2019 CHEST guidelines note that while the GRIPHON trial showed significant reduction in the composite endpoint, there was no significant difference in PAH mortality alone (HR 0.86,95% CI 0.63-1.18, P=0.18) or all-cause mortality (HR 0.97, P=0.42) 6. The 6-minute walk distance improvement (12 meters) did not meet the predefined minimally important difference of 33 meters 6.

Despite these limitations, the 2016 ESC/ERS guidelines recognize selexipag's ability to reduce the composite morbidity/mortality endpoint by 40% when used as monotherapy or added to ERA and/or PDE-5 inhibitor therapy 3. Real-world studies demonstrate better outcomes in patients who achieve low or intermediate-low risk status, with 1-year survival of 100% and 96% respectively 5.

Practical Titration Approach

In real-world practice, successful titration to individualized maintenance doses occurs in approximately 54% of patients, with the remainder requiring dose adjustments or discontinuation 2, 7. The key is slow, patient-specific titration rather than rigid adherence to weekly increases if tolerability is an issue. Outpatient titration is safe and effective 7.